SCHEMBL754646

SCHEMBL754646

CC(=O)N(N)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
S100A4 P26447 1/20 0.44
APP P05067 2/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
KCNN4 O15554 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
NR3C2 P08235 1/20 0.36
AOC3 Q16853 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4633234 0.82 TSHR (0.56) TSHRS100A4APPCES2CES1
SCHEMBL1266868 0.80 CES2 (0.41) APPCES2CES1KCNN4ALDH1A1
SCHEMBL9328858 0.80 CYP3A4 (0.46) TSHRNOS3NOS1ALDH1A1MAPT
SCHEMBL7036611 0.80 ALDH1A1 (0.46) TSHRCES2CES1ALDH1A1MAPT
SCHEMBL5663915 0.80 ESR1 (0.41) TSHRAPPNOS3ALDH1A1MAPT
SCHEMBL5736585 0.78 APP (0.41) APPALDH1A1MAPTCA1CA2
SCHEMBL19527562 0.78 NOS3 (0.39) TSHRS100A4APPNOS3NOS1
SCHEMBL28228853 0.78 MAPT (0.44) TSHRS100A4APPNOS3NOS1
SCHEMBL7032266 0.78 MAPT (0.42) TSHRCES2CES1NOS1ALDH1A1
SCHEMBL10441524 0.78 MT-CO2 (0.46) TSHRCES2CES1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109467528-B Synthesis method of 1-aminoindole derivative 佛山科学技术学院 2020-11-06 CN disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-1422218-B1 ANTIVIRAL AGENT SHIONOGI & CO (JP) 2012-03-21 EP disclosed
EP-2181985-B1 Antiviral Agent SHIONOGI & CO (JP) 2011-10-26 EP disclosed
EP-2181985-A1 Antiviral Agent SHIONOGI & CO., LTD. (JP) 2010-05-05 EP disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT TSHR 4237/4885S100A4 4810/4885APP 3873/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI TSHR 3427/4885S100A4 4681/4885APP 4073/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI TSHR 3427/4885S100A4 4681/4885APP 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.